Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/30/2026

1. SPY
2. CRWV
3. DASH
4. BA
5. CCL
6. MU
7. MDB
8. AMZN
9. GOOGL
10. LLY

Go back to Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
(NASDAQ: APVO) Delayed: 1.82 -0.04 (2.15%)
Previous Close $1.86    52 Week High $4.33 
Open $1.84    52 Week Low $1.80 
Day High $1.90    P/E N/A 
Day Low $1.81    EPS $0.00 
Volume 23,824